Japan Approves GSK's Antibody Treatment For COVID-19 Patients

Sotrovimab will be used for COVID 19 patients with mild symptoms, says Japanese Health Ministry.

Japan on Monday approved GlaxoSmithKline and and Vir Biotechnology's Sotrovimab for treatment of patients with mild COVID-19 symptoms.
Japan's Health Ministry authorized the use of the antibody treatment on the recommendation of a panel of experts.
Sotrovimab, which is administered intravenously, will be used for COVID-19 patients who do not require oxygen supplementation.
Clinical tests showed the drug reduces the risk of hospitalization and death by 79%.​​​​​​​ -